Medication Guides
Updated August 6, 2026

Rybelsus Savings Card 2026: $25/Month Guide & Ozempic Pill Update

Evan Brown
Written by Evan Brown
Prescription Savings Researcher
Dr Megan Harris Medically Reviewed by Dr. Megan Harris, MD
Medical Review: This guide explains Novo Nordisk's copay assistance program for Rybelsus (oral semaglutide) and the 2026 transition to the Ozempic pill, including the $25 monthly cap, eligibility rules, and what to do if you don't qualify. Program terms are set by Novo Nordisk and can change, so always confirm current details at enrollment.
Quick Answer

The Rybelsus Savings Card, issued through NovoCare, caps out-of-pocket costs at as little as $25 for a 1-, 2-, or 3-month supply of oral semaglutide, with maximum savings of $100 per month, $200 per two months, or $300 per three months. You need commercial insurance that covers the medication — unlike some insulin cards, this program does not cover uninsured, cash-paying patients, and it's off-limits to anyone on Medicare, Medicaid, or other government insurance.

Here's the twist most pages miss: as of May 2026, Rybelsus is being retired. Novo Nordisk has relaunched oral semaglutide for type 2 diabetes under the more familiar Ozempic brand — the "Ozempic pill," in new 1.5 mg, 4 mg, and 9 mg strengths. If your pharmacist says they can't find "Rybelsus" anymore, this is why, and the same NovoCare savings card now applies to the new tablet.

Name change alert: If you were prescribed Rybelsus 3 mg, 7 mg, or 14 mg and your refill suddenly shows up labeled Ozempic 1.5 mg, 4 mg, or 9 mg, that's not a pharmacy error. Novo Nordisk reformulated oral semaglutide for a smaller pill and better absorption, then folded it into the Ozempic brand starting in May 2026. The active ingredient, dose strength relationship, and clinical use for type 2 diabetes are unchanged — only the name, milligram numbers, and tablet size are different.

Key Takeaways

  • The savings card price moved from $10 to $25 per month effective January 2, 2026, with maximum savings capped at $100–$300 depending on supply length.
  • Rybelsus is being phased out and replaced by the Ozempic pill (1.5 mg, 4 mg, 9 mg) — the same NovoCare card now covers both during the transition.
  • You must have commercial insurance with product coverage. Uninsured patients and anyone on government insurance cannot use this card.
  • The card stays active for up to 48 months after online activation — no yearly re-enrollment required, unlike many manufacturer cards.
  • Uninsured patients now have a new option that didn't exist under the old Rybelsus branding: NovoCare Pharmacy self-pay pricing starting around $149/month, plus the income-qualified NovoCare Patient Assistance Program for free medication.

Rybelsus / Ozempic Pill With Savings Card

$25/month

Commercial insurance required · max $100–$300 savings per fill

Rybelsus (oral semaglutide) was the first pill version of a GLP-1 medication approved for type 2 diabetes, and for years it was the only way to get semaglutide without an injection. That changed in 2026. Novo Nordisk didn't just tweak the price of its savings program — it retired the Rybelsus name entirely and moved oral semaglutide for diabetes under the Ozempic brand, with a smaller, reformulated tablet.

If you're searching for a "Rybelsus savings card," you're probably in one of three situations: you're still on Rybelsus tablets and want to keep your cost low, your prescription just switched to the new Ozempic pill and you're not sure if your savings card still works, or you're trying to figure out why your pharmacy can't find "Rybelsus" in their system anymore. This guide covers all three, along with the eligibility rules, income limits, and enrollment steps that apply either way.

Everything below reflects program terms as of August 2026. Because Novo Nordisk is actively mid-transition on branding and pricing, it's worth reverifying details directly with NovoCare before you rely on any specific dollar figure at the pharmacy counter.

What the Rybelsus Savings Card Actually Covers Now

The program patients call the "Rybelsus Savings Card" is officially the NovoCare Diabetes Savings Card. It's a manufacturer copay assistance program, not insurance, and it works by reducing what you owe at the pharmacy register after your insurance processes the claim. As of NovoCare's current program terms, effective January 2, 2026, eligible commercially insured patients pay as little as $25 for a covered prescription, down from a previous $10 offer.

The card isn't tied to the "Rybelsus" name specifically — it applies to oral semaglutide for type 2 diabetes regardless of which brand name is on the label. That matters a lot right now, because the label is actively changing for most patients.

Program Detail Current Terms (Aug 2026)
Cost with card (commercial insurance) As little as $25 per fill
Max savings, 1-month supply $100
Max savings, 2-month supply $200 (7 mg/14 mg or 4 mg/9 mg only)
Max savings, 3-month supply $300 (7 mg/14 mg or 4 mg/9 mg only)
Lowest dose (3 mg / 1.5 mg) Limited to a 1-month fill per redemption, $100 max
Card validity Up to 48 months after online activation
Uninsured / cash-pay patients Not eligible for the copay card
Government insurance (Medicare, Medicaid, TRICARE) Excluded by federal law

Why the price went up: Many older blog posts and coupon sites still advertise "Rybelsus for $10." That offer ended January 2, 2026. If a page you find quotes $10, it's out of date — the current floor is $25.

Rybelsus to Ozempic Pill: What Actually Changed

This is the part most competing guides gloss over, and it's the single most important update for anyone searching "Rybelsus" in the second half of 2026.

In February 2026, Novo Nordisk announced it would retire the Rybelsus brand name in the US and move oral semaglutide for type 2 diabetes under the Ozempic name. The company officially launched the reformulated tablet — the "Ozempic pill" — nationwide in May 2026. It's the same active ingredient, semaglutide, but the tablet itself is smaller, uses a different coating, and has improved bioavailability, which is why the milligram doses changed even though the clinical effect is meant to stay equivalent.

According to Novo Nordisk's own explanation of the change, reported by industry outlets covering the company's 2026 newsroom announcements, the goal was to stop splitting brand recognition between "Ozempic" (the well-known injectable) and "Rybelsus" (the pill most patients had never heard of) when both contain the same drug. Rolling both under one brand name was framed as a way to reduce patient and prescriber confusion — and, not coincidentally, to lean on the name recognition Ozempic had already built.

  • Rybelsus tablets may still be dispensed during a transition period, so you might still see the old name on a bottle you already have.
  • New prescriptions are increasingly being written for the Ozempic pill under its new dose strengths.
  • Pharmacies cannot swap you from one to the other without a new prescription from your provider, even though the drug is the same.
  • The NovoCare savings card program itself did not restart — it's the same card, same eligibility rules, just now applied to a product with a new name and new milligram numbers.

If your dose looks different, don't panic — check the math first. Rybelsus 3 mg is roughly equivalent to Ozempic pill 1.5 mg, Rybelsus 7 mg to Ozempic pill 4 mg, and Rybelsus 14 mg to Ozempic pill 9 mg, according to Novo Nordisk's own dose mapping. These aren't identical milligram-for-milligram doses of the same formulation — they're different formulations designed to produce a comparable effect. Confirm any dose change with your prescriber rather than assuming the numbers line up on their own.

Is There a Rybelsus Coupon?

There's no separate printable "coupon" for Rybelsus. Novo Nordisk doesn't issue traditional manufacturer coupons for its GLP-1 medications. What people mean when they search "Rybelsus coupon" is almost always the NovoCare savings card described above — it functions the same way a coupon would at checkout, just processed electronically through your pharmacy's system.

What Patients Search For What Actually Exists How It Works
Rybelsus coupon NovoCare Savings Card Manufacturer copay card applied electronically at the pharmacy — no printable coupon involved
Rybelsus manufacturer coupon NovoCare Savings Card Same program. Novo Nordisk does not issue printable coupons for this drug class.
Ozempic pill savings card NovoCare Savings Card Same card, same terms, now applied to the relaunched tablet
Rybelsus free trial New-patient bridge offers (availability varies) Some prescribers can offer short bridge samples through NovoCare while insurance approval is pending
Third-party Rybelsus discount card GoodRx, SingleCare, Inside Rx Cannot be combined with the NovoCare card on the same fill. Compare and use whichever is lower.

For a broader look at how manufacturer cards stack up against pharmacy discount programs generally, our GoodRx vs. Inside Rx comparison walks through when a discount card actually beats a brand-name copay card.

Dose Equivalents: Rybelsus vs. the Ozempic Pill

Because both names are circulating right now, it helps to see the two products side by side. Neither is a generic of the other — they're the same manufacturer's two generations of the same molecule.

Rybelsus (legacy) Ozempic Pill (current) Status
3 mg tablet 1.5 mg tablet Ozempic pill is the current formulation
7 mg tablet 4 mg tablet Ozempic pill is the current formulation
14 mg tablet 9 mg tablet Ozempic pill is the current formulation
Manufacturer Novo Nordisk, both products
Approved use Type 2 diabetes; oral semaglutide also has FDA approval for reducing major cardiovascular events in adults with T2D and high cardiovascular risk
Savings card eligibility Identical — same NovoCare program, same $25 floor

Not for weight loss: Neither Rybelsus nor the Ozempic pill is FDA-approved for weight management. Novo Nordisk's oral semaglutide for weight loss is a separate product, the Wegovy pill, at its own doses and its own savings program. If your prescription is for weight management rather than type 2 diabetes, the eligibility rules in this guide may not apply — check the Wegovy-specific savings terms instead.

Who Qualifies for the $25 Cap

Insurance Situation Eligible? Notes
Commercial/private insurance, plan covers the drug Yes Card reduces your copay to as low as $25
Commercial insurance, drug not on formulary Not automatically Coverage denial usually needs to be resolved first — see our prior authorization guide
Uninsured / self-pay No Use NovoCare Pharmacy self-pay pricing or apply for the PAP instead
Medicare (Part D or Advantage) No Barred by federal anti-kickback rules for manufacturer copay cards
Medicaid No State Medicaid formulary and copay rules apply instead
TRICARE / VA / other government insurance No Excluded under program terms and federal law
  • You have commercial or private health insurance
  • Your plan provides some coverage for Rybelsus or the Ozempic pill for type 2 diabetes
  • You're a US resident (states and territories, including Puerto Rico)
  • You're 18 or older
  • You have no insurance at all
  • You're enrolled in Medicare, Medicaid, TRICARE, or another government plan
  • Your prescription is for weight management rather than type 2 diabetes

Income Limits: Savings Card vs. Patient Assistance

The NovoCare savings card has no income requirement at all — eligibility is based entirely on insurance status, not what you earn. That's different from the separate NovoCare Patient Assistance Program (PAP), which exists specifically for patients the copay card can't help.

Program Income Requirement Insurance Requirement What You Pay
NovoCare Savings Card None Commercial insurance with coverage As little as $25/month
NovoCare Pharmacy (self-pay) None None required ~$149–$299/month depending on dose
NovoCare Patient Assistance Program Generally at or below 400% of the Federal Poverty Level Uninsured or underinsured $0

In practice, work through these in order: check whether your insurance already gets you close to $25, then check NovoCare Pharmacy's self-pay price if you're uninsured, and only pursue the full PAP application if $149–$299 a month is still out of reach. The PAP application takes longer and requires income documentation, so it's worth confirming you actually need it before starting. For a wider list of income-based options across manufacturers, see our patient assistance program directory, and independent tools like NeedyMeds or BenefitsCheckUp for state and nonprofit assistance layered on top.

Covered Medications and Fill Limits

The NovoCare Diabetes Savings Card program covers several Novo Nordisk products under related terms, though the specific caps differ by product and dose.

Medication Covered Under This Program? Fill Limit
Rybelsus 3 mg / 7 mg / 14 mg Yes (during transition) 1–3 month supply depending on dose
Ozempic pill 1.5 mg / 4 mg / 9 mg Yes 1–3 month supply depending on dose
Ozempic injection (semaglutide) Yes, under the related Ozempic savings offer Varies by fill length and current promotional terms
Wegovy pill / injection Separate program Not covered under the diabetes savings card

Step-by-Step: How to Enroll

1

Confirm your prescription's actual name and dose

Check whether your current prescription is still written as Rybelsus or has moved to the Ozempic pill. Either way, the savings card terms below apply the same way.

2

Verify your insurance covers the medication

Call your insurer or check your plan's formulary. If it's not covered, the savings card can't apply until coverage is sorted out — start with our prior authorization guide if you've hit a denial.

3

Activate your savings card

Sign up online at rybelsus.com/savings-and-support or novocare.com, or text READY to 21848 to enroll and receive a digital card by text.

4

Present the card with your prescription

Give your pharmacist the savings card details along with your prescription at any participating retail pharmacy. It's applied automatically at checkout in most cases.

5

Confirm your out-of-pocket price before paying

Ask the pharmacist to confirm the card was applied and that your cost reflects the current $25 floor before you complete the transaction.

Decision Tree: Which Program Fits You?

What's your coverage?

Start here to route to the right program

Commercial Insurance

NovoCare Savings Card

As little as $25/month, up to 48 months

Uninsured

NovoCare Pharmacy Self-Pay

~$149–$299/month, no insurance needed

Medicare / Medicaid

Plan-Specific Coverage

Check Part D formulary or state Medicaid rules

Still can't afford it?

Apply to the NovoCare Patient Assistance Program for free medication

Approval Timelines: What to Expect

Program Typical Timeline
NovoCare Savings Card activation Immediate — same-day digital enrollment
NovoCare Pharmacy self-pay order Same day to a few business days for shipment
NovoCare Patient Assistance Program Typically 2–4 weeks after a complete application with prescriber signature
Prior authorization (if your plan requires it) Usually 3–14 business days, longer if appealed

Renewing the Card: The 48-Month Rule

One genuinely useful detail that separates this program from a lot of manufacturer copay cards: it's valid for up to 48 months from the date you activate it online, not just a single calendar year. You don't need to re-enroll annually the way you would with many insulin savings cards.

  • Mark your activation date somewhere you'll remember it, since the 48-month window is tied to that date, not the calendar year.
  • Even within the 48-month window, Novo Nordisk can still change pricing terms — the January 2026 jump from $10 to $25 happened mid-program for existing cardholders.
  • If your prescription switches from Rybelsus to the Ozempic pill, your existing card generally continues to work; you don't need a brand-new card just because the label changed.
  • If your insurance changes — a new employer plan, a new formulary tier — reverify at the pharmacy rather than assuming your old card terms still apply exactly.

List Price vs. Out-of-Pocket Cost

List price is what's billed before any discount. Out-of-pocket cost is what you actually pay once insurance and the savings card are applied. For oral semaglutide, the gap between those two numbers is large.

Product Approx. Cash/List Price With Savings Card NovoCare Pharmacy Self-Pay
Rybelsus (legacy, all doses) ~$950–$1,100/month As low as $25 Not offered under this branding
Ozempic pill 1.5 mg ~$950–$1,100/month list As low as $25 ~$149/month
Ozempic pill 4 mg ~$950–$1,100/month list As low as $25 ~$199/month
Ozempic pill 9 mg ~$950–$1,100/month list As low as $25 ~$299/month

The self-pay option is new — and it matters for uninsured patients. Under the old Rybelsus branding, uninsured patients had essentially one option: full list price near $1,000 a month, unless they qualified for the income-based PAP. The Ozempic pill relaunch introduced a direct-to-patient self-pay price through NovoCare Pharmacy, which is a meaningfully lower number even without insurance or income qualification. Use our Drug Price Checker to compare this against retail cash prices at pharmacies near you.

If You Don't Qualify: Other Ways to Save

If you're uninsured, underinsured, or on government insurance, the copay card genuinely isn't available to you — no amount of asking a pharmacist to "just run it as commercial" will work, and trying can create billing problems. Here's what actually applies instead.

Situation Best Option
Uninsured, moderate income NovoCare Pharmacy self-pay (~$149–$299/month)
Uninsured, income at or below ~400% FPL NovoCare Patient Assistance Program (free)
Insured, but drug isn't covered Prior authorization or formulary exception — see our prior authorization guide
Medicare Part D enrollee Rely on your plan's annual out-of-pocket cap; see Medicare Part D & GLP-1 coverage and Extra Help (LIS) if income-qualified
Any patient comparing pharmacy prices Compare cash-discount cards like GoodRx or Inside Rx against NovoCare Pharmacy — see our GoodRx vs. Inside Rx comparison

You can apply to the NovoCare PAP directly through novocare.com, and it's worth cross-checking eligibility against other resources in our patient assistance program directory, since some patients qualify for state or nonprofit help layered on top of a manufacturer program. The Medicare.gov Part D cost page and CMS.gov are the most reliable sources for how the federal insulin and drug cost caps interact with GLP-1 coverage if you're on Medicare.

Pros and Cons of the NovoCare Savings Card

Pros Cons
Valid for up to 48 months — no annual re-enrollment Not available to uninsured or cash-pay patients
No income requirement to qualify Price rose from $10 to $25 in January 2026
Works automatically at most major pharmacies Excluded for Medicare, Medicaid, and other government insurance
Continues to apply through the Rybelsus-to-Ozempic pill transition Maximum savings caps at $100–$300, so very high copays may not hit $25

Common Mistakes That Cost Patients Money

  • Assuming the $10 price still applies — it changed to $25 on January 2, 2026.
  • Not realizing "Ozempic pill" and "Rybelsus" are the same drug, and switching prescriptions without confirming the dose equivalent with a provider.
  • Trying to use the copay card as an uninsured patient, which will be rejected at the register.
  • Assuming a card that worked for Rybelsus won't work for the Ozempic pill — it will, as long as your insurance and eligibility haven't changed.
  • Stacking a GoodRx or SingleCare coupon with the NovoCare card on the same fill, which pharmacies generally won't process.
  • Forgetting your activation date and assuming the card expired after one year, when it's actually valid for up to 48 months.

Real Patient Scenarios

Scenario 1 — Prescription switched mid-treatment: A patient on Rybelsus 7 mg for eight months gets a refill labeled "Ozempic 4 mg" without much explanation from the pharmacy. Her existing NovoCare savings card still applies, and her out-of-pocket cost stays at $25, once her provider confirms the dose change is intentional.

Scenario 2 — Uninsured and quoted $1,000: A self-employed patient with no insurance is quoted close to list price for the Ozempic pill 4 mg. Because he's uninsured, the NovoCare savings card isn't an option — but the newer NovoCare Pharmacy self-pay price brings his monthly cost down to around $199 instead.

Scenario 3 — High-deductible plan, early in the year: A patient with a high-deductible employer plan is billed $410 in January because she hasn't met her deductible yet. The NovoCare savings card applies its full $100 monthly maximum, bringing her cost down to $310 — still above the advertised $25, because her copay before the card exceeded what the card's maximum can offset.


Bottom Line

The core NovoCare savings program hasn't gone away — it's the branding on top of it that changed. If you have commercial insurance that covers oral semaglutide, the $25 floor still applies whether your bottle says Rybelsus or the newer Ozempic pill. If you're uninsured, the meaningful shift in 2026 is that a direct self-pay price now exists where there wasn't one before.

Whatever your situation, don't assume last year's price or last year's brand name still applies without checking. Confirm current terms at enrollment, and ask your pharmacist to show you the exact price before you pay.


Frequently Asked Questions

It's Novo Nordisk's manufacturer copay assistance program for oral semaglutide, run through NovoCare. Eligible patients with commercial insurance that covers the medication can pay as little as $25 for a 1-, 2-, or 3-month supply, depending on dose and prescription length.

Rybelsus is being phased out. As of May 2026, Novo Nordisk relaunched oral semaglutide for type 2 diabetes under the Ozempic brand as the "Ozempic pill," in new 1.5 mg, 4 mg, and 9 mg strengths. Rybelsus tablets may still be dispensed during the transition, but new prescriptions are increasingly being written for the Ozempic pill instead.

There is no separate printable manufacturer coupon. The NovoCare savings card functions as the coupon at the pharmacy counter, reducing eligible patients' cost to as little as $25 per fill. This same card now applies to both remaining Rybelsus prescriptions and the new Ozempic pill.

No. Unlike some insulin copay cards, this program requires commercial insurance with coverage for the product. Cash-paying, uninsured patients are excluded from the copay card but can use NovoCare Pharmacy's self-pay pricing or apply to the NovoCare Patient Assistance Program instead.

Without insurance, Rybelsus historically listed near $997 to $1,100 per month. Uninsured patients switched to the newer Ozempic pill can instead use NovoCare Pharmacy's self-pay pricing, which starts around $149 per month for the 1.5 mg dose, $199 for 4 mg, and $299 for 9 mg, or apply for free medication through the NovoCare Patient Assistance Program if income-qualified.

No. Federal law prohibits manufacturer copay cards for patients enrolled in Medicare, Medicaid, TRICARE, or other government-funded insurance. Medicare Part D enrollees instead benefit from the plan's own annual out-of-pocket cap on covered drugs — see our Medicare Part D & GLP-1 coverage guide.

The card is valid for up to 48 months after online activation, which is longer than many manufacturer copay programs. Patients don't need to reapply every year, though pricing terms and eligibility rules can still change during that window, as happened in January 2026.

Yes, in the sense that both contain semaglutide and treat type 2 diabetes. The Ozempic pill is a reformulated, smaller tablet with different milligram strengths (1.5 mg, 4 mg, 9 mg) approved to replace Rybelsus (3 mg, 7 mg, 14 mg) going forward, with Novo Nordisk stating comparable efficacy and safety.

Not without a new prescription. Pharmacies cannot substitute between the two products on their own, even though they're made by the same manufacturer and treat the same condition. Any switch needs to come from your prescriber.

Generally no. Pharmacies typically process one discount per transaction, so compare the NovoCare card price against GoodRx, SingleCare, or Inside Rx pricing and use whichever comes out lower for your situation.

The card is accepted at most major retail pharmacies, including CVS, Walgreens, Walmart, and Kroger, as well as many independent pharmacies. If your pharmacist can't find the program, ask them to look it up as a NovoCare manufacturer copay card for oral semaglutide.

They're related but separate offers under NovoCare's broader diabetes savings program. Oral semaglutide (Rybelsus/Ozempic pill) and injectable Ozempic have their own specific pricing and fill-length terms, so check the product-specific terms rather than assuming one automatically applies to the other.

No. Rybelsus and the Ozempic pill are approved for type 2 diabetes, not weight management. Novo Nordisk's oral semaglutide for weight loss is marketed separately as the Wegovy pill, with its own dosing and its own savings program.


How We Researched This Guide

This guide was prepared by the Refill Relay Editorial Team using Novo Nordisk's official NovoCare savings program terms, published reporting on the 2026 Rybelsus-to-Ozempic pill rebrand, and independent pharmacy pricing resources.

Every article undergoes editorial review for accuracy, readability and consistency before publication. Program terms, dose strengths and pricing are controlled by Novo Nordisk and subject to change — always confirm current details before enrolling.


Sources

  1. NovoCare — Diabetes Savings Card Program (official terms)
  2. Rybelsus.com — Cost & Savings Card
  3. Novo Nordisk — 2026 US Newsroom Announcements
  4. U.S. Food and Drug Administration — Drug Approvals and Databases
  5. Medicare.gov — Part D Prescription Drug Costs
  6. Centers for Medicare & Medicaid Services (CMS)

About Refill Relay

Refill Relay publishes evidence-based educational resources that help patients understand prescription costs, manufacturer savings programs and medication access. Our editorial team combines pricing research with practical guidance to make complex affordability programs easier to navigate.

Editorial Standards

  • Evidence-based research using manufacturer and pharmacy sources
  • Clinical review before publication
  • Regular updates when program terms or brand names change
  • Clear distinction between educational content and personalized financial advice

Editorial Policy: Refill Relay medical content is researched using manufacturer program terms, FDA prescribing information and pharmacist-reviewed pricing resources. Every article is reviewed for clarity, accuracy and usefulness before publication. Program eligibility, pricing and brand names are controlled by Novo Nordisk and subject to change without notice.

Evan Brown
About the Author
Evan Brown — Prescription Savings Researcher

Evan Brown is a medical content researcher who specializes in translating manufacturer savings programs and insurance rules into clear, actionable guidance for patients.

View Full Profile →
Dr. Megan Harris, MD
Medical Review
Dr. Megan Harris, MD

Dr. Megan Harris, MD reviews health content for medical accuracy, checking program eligibility and drug information against current manufacturer and FDA guidance.

View Full Profile →

Contact Refill Relay